Related references
Note: Only part of the references are listed.Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
Cristina Gasparetto et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes
Jay L. Patel et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath et al.
BLOOD CANCER JOURNAL (2021)
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry
Hans C. Lee et al.
BLOOD CANCER JOURNAL (2021)
Association between race and treatment patterns and survival outcomes in multiple myeloma: A connect MM registry analysis
Sikander Ailawadhi et al.
CANCER (2020)
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Caitlin Costello et al.
FUTURE ONCOLOGY (2019)
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
Celestia S. Higano et al.
CANCER (2019)
PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE
H. Goldschmidt et al.
VALUE IN HEALTH (2019)
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry
Anthony Mato et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect VR CLL cohort study
Christopher R. Flowers et al.
LEUKEMIA & LYMPHOMA (2018)
HEALTH-RELATED QUALITY OF LIFE ASSESSMENTS PREDICT RELAPSE OR DEATH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE CONNECT MM REGISTRY
I Wagner et al.
VALUE IN HEALTH (2018)
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the ConnectA® MM Registry
Rafat Abonour et al.
ANNALS OF HEMATOLOGY (2018)
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Robert M. Rifkin et al.
CLINICAL THERAPEUTICS (2018)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Early progression of disease as a predictor of survival in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD ADVANCES (2017)
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes
Jatin J. Shah et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States
Chadi Nabhan et al.
BMC CANCER (2017)
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
David P. Steensma et al.
BMC CANCER (2016)
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era
Loretta J. Nastoupil et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
Jorge A. Marrero et al.
JOURNAL OF HEPATOLOGY (2016)
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study
C. Casulo et al.
ANNALS OF ONCOLOGY (2015)
Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics
Robert M. Rifkin et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study
A. J. Wozniak et al.
CLINICAL ONCOLOGY (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry
David L. Grinblatt et al.
LEUKEMIA & LYMPHOMA (2015)
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry
Simone Oerlemans et al.
ANNALS OF HEMATOLOGY (2014)
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Debu Tripathy et al.
BMC CANCER (2014)
The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States
Loretta J. Nastoupil et al.
CANCER (2014)
Assessing the Discordance Rate Between Local and Central HER2 Testing in Women With Locally Determined HER2-Negative Breast Cancer
Peter A. Kaufman et al.
CANCER (2014)
Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry - Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study
H. I. Hurwitz et al.
CLINICAL ONCOLOGY (2014)
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Axel Grothey et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
A. K. Nooka et al.
ANNALS OF ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Understanding Commonly Encountered Limitations in Clinical Research: An Emergency Medicine Resident's Perspective
Christopher W. Jones et al.
ANNALS OF EMERGENCY MEDICINE (2012)
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States
Chadi Nabhan et al.
CANCER (2012)
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
Johanna C. Bendell et al.
ONCOLOGIST (2012)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Adam M. Brufsky et al.
CLINICAL CANCER RESEARCH (2011)
Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva
Nicole M. Seminara et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2010)
Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer
Marc Buyse
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The evolution of the population-based cancer registry
Donald M. Parkin
NATURE REVIEWS CANCER (2006)
Share Paper
